Molecular alterations in odontogenic keratocysts as potential therapeutic targets

Carolina Cavalieri Gomes1, Letícia Martins Guimarães2, Marina Gonçalves Diniz2

  • 1Department of Pathology, Basic Sciences Institute, Universidade Federal de Minas Gerais-UFMG, Belo Horizonte, Brazil.

Insights

Odontogenic keratocysts (OKCs) are cystic lesions with a tendency to recur. Research reveals molecular alterations in OKC pathogenesis, including PTCH1 mutations and Hedgehog pathway disturbances, offering potential therapeutic targets.

Area of Science:

  • Oral pathology
  • Molecular oncology
  • Developmental biology

Background:

  • Odontogenic keratocyst (OKC) is a common cystic lesion of the jaw.
  • Characterized by thickened parakeratinized epithelium and a high recurrence rate post-surgery.
  • The neoplastic potential of OKCs is debated, necessitating further investigation into their molecular underpinnings.

Purpose of the Study:

  • To review and synthesize recent findings on the molecular mechanisms driving OKC pathogenesis.
  • To identify molecular alterations that could serve as therapeutic targets for OKC treatment.
  • To clarify the molecular basis of OKC development and behavior.

Main Methods:

  • Review of recent scientific literature on OKC molecular pathogenesis.
  • Analysis of studies investigating genetic mutations, gene expression, and epigenetic modifications in OKCs.
  • Exploration of signaling pathways implicated in OKC development, such as the Hedgehog pathway.

Main Results:

  • Sporadic OKCs frequently harbor PTCH1 mutations, occurring more often than previously recognized.
  • Hedgehog pathway dysregulation and Bcl-2 protein overexpression are observed in OKCs.
  • Recent studies highlight alterations in DNA methylation and microRNA expression in these lesions.

Conclusions:

  • OKCs exhibit complex molecular alterations contributing to their pathogenesis and aggressive behavior.
  • Understanding these molecular changes, including PTCH1 mutations and pathway disturbances, is crucial.
  • Targeting these identified molecular pathways presents a promising avenue for future OKC therapies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.6K